Columbia, SOUTH%20CAROLINA3 Active Studies

Pulmonary Hypertension Clinical Trials in Columbia, SOUTH%20CAROLINA

Find 3 actively recruiting pulmonary hypertension clinical trials in Columbia, SOUTH%20CAROLINA. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
203
Enrolling

Recruiting Pulmonary Hypertension Studies in Columbia

About Pulmonary Hypertension Clinical Trials in Columbia

Pulmonary hypertension is a type of high blood pressure that affects the arteries in the lungs and the right side of the heart. It can lead to heart failure if untreated. Treatment includes vasodilators, endothelin receptor antagonists, and PDE-5 inhibitors.

There are currently 3 pulmonary hypertension clinical trials recruiting participants in Columbia, SOUTH%20CAROLINA. These studies are seeking a combined 203 participants. Research is being sponsored by Johns Hopkins University, University of Maryland, Baltimore, NMD Pharma A/S. Clinical trial participation is free and participants receive study-related medical care at no cost.

Pulmonary Hypertension Clinical Trials in Columbia — FAQ

Are there pulmonary hypertension clinical trials in Columbia?

Yes, there are 3 pulmonary hypertension clinical trials currently recruiting in Columbia, SOUTH%20CAROLINA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Columbia?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Columbia research site will contact you about next steps.

Are clinical trials in Columbia free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Columbia studies also compensate for your time and travel.

What pulmonary hypertension treatments are being tested?

The 3 active trials in Columbia are testing new therapies including novel drugs, biologics, and treatment approaches for pulmonary hypertension.

Data updated March 2, 2026 from ClinicalTrials.gov